BMC Public Health | |
Identifying predictors of blood pressure control in the Lebanese population - a national, multicentric survey – I-PREDICT | |
Marie-Thérèse Sawaya1  Fariha Younes1  Serena Abu Samra1  Samir G Mallat2  | |
[1] Medical Affairs Department, Sanofi-aventis Liban, Omar Daouk Street, Starco Building, 1st Floor, Bloc B, P.O. Box 110697, Beirut, Lebanon;Department of Internal Medicine, American University of Beirut, Riad El-Solh, P.O. Box 11–0236, Beirut 11072020, Lebanon | |
关键词: Predictors; Guidelines; Control; Blood pressure; Anti-hypertensive drugs; | |
Others : 1123048 DOI : 10.1186/1471-2458-14-1142 |
|
received in 2014-02-20, accepted in 2014-09-29, 发布年份 2014 | |
【 摘 要 】
Background
Blood Pressure (BP) is not well controlled and factors that predict BP control are not well identified in Lebanon. Improvement of hypertension management requires an understanding of patients’ characteristics and factors associated with uncontrolled BP. This national, multicentric, observational prospective study was designed to determine the predictors of BP control in patients followed up to 6 months.
Methods
I-PREDICT study was conducted on 988 patients with newly diagnosed or uncontrolled hypertension. Socio-demographic and clinical characteristics were analyzed. The level of agreement between doctors’ perceptions on BP control status and JNC VII guidelines was analyzed.
Results
The predictor associated with poor BP control was diabetes (OR = 0.17, CI = 0.10–0.28 at month-1; OR = 0.15, CI = 0.10–0.24 at month-6). The predictors associated with better BP control at month-6 were the early control of BP at month-1 (OR = 10.39, CI = 6.18–17.47) and combination therapy prescribed at baseline and month-1 (OR = 15.14, CI = 1.09–208.46, P = 0.04). In the sub-group of diabetes, the predictors that were associated with better BP control at 6 months were following diet at V1 (OR = 2.27, CI = 1.01 to 5.12) and BP control at V2 (OR = 7.34, CT = 3.83 to 14.07). The predictors that were associated with poor BP control at 6 months were middle economic class (OR = 0.036, CI = 0.16-0.94) and upper economic class (OR = 0.036; CI = 0.13-0.93).
The rate of BP control was significantly higher at month 6 versus month 1 (67.52% vs 44.08%, P = 0.001). Additional analysis showed poor agreement between the doctors’ perceptions on BP control status and the guidelines.
Conclusions
Reaching an early BP control and combination therapy were significant predictors of better BP control, whereas diabetes was a significant predictor of poor BP control. A poor agreement between JNC VII guidelines and clinical practice was observed. I-PREDICT study identified factors that can be targeted for improving BP control.
【 授权许可】
2014 Mallat et al.; licensee BioMed Central Ltd.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20150215030942719.pdf | 353KB | download | |
Figure 1. | 31KB | Image | download |
【 图 表 】
Figure 1.
【 参考文献 】
- [1]World Health Organization: Global health risks. Mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2009. Available from: http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf webcite. Last access: 26th of July 2013
- [2]Ibrahim MM, Damasceno A: Hypertension in developing countries. Lancet 2012, 380(9841):611-619.
- [3]World Health Organization: WHO Global Report. Preventing chronic disease: a vital investment. Geneva, Switzerland: World Health Organization; 2005. Available from: http://www.who.int/chp/chronic_disease_report/full_report.pdf webcite. Last access: 26th of July 2013
- [4]Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
- [5]Fuentes R, Ilmaniemi N, Laurikainen E, Tuomilehto J, Nissinen A: Hypertension in developing economies: a review of population-based studies carried out from 1980 to 1998. J Hypertens 2000, 18:521-529.
- [6]World Health Organization: NCD Country Profiles, 2011. Geneva, Switzerland: World Health Organization; 2011. Available from: http://www.who.int/nmh/countries/lbn_en.pdf webcite
- [7]Jarraya F, Kammoun K, Mahfoudh H, Kammoun K, Hachicha J: Management of arterial hypertension in Tunisia: the challenge of a developing country. Rev Med Suisse 2012, 8:1725-1726. 1728–1730. [Article in French]
- [8]Sarafidis PA, Lasaridis A, Gousopoulos S, Zebekakis P, Nikolaidis P, Tziolas I, Papoulidou F: Prevalence, awareness, treatment and control of hypertension in employees of factories of northern Greece: the Naoussa Study. J Hum Hypertens 2004, 18(9):623-629.
- [9]Altun B, Arici M, Nergizoğlu G, Derici U, Karatan O, Turgan C, Sindel S, Erbay B, Hasanoğlu E, Cağlar S, Turkish Society of Hypertension and Renal Diseases: Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003. J Hypertens 2005, 23:1817-1823.
- [10]Brown DW, Mokdad AH, Walke H, As’ad M, Al-Nsour M, Zindah M, Arqoob K, Belbeisi A: Projected burden of chronic, noncommunicable diseases in Jordan [letter]. Prev Chronic Dis 2009, 6(2):A78.
- [11]Lebanese Interventional Coronary Registry: Findings 2011. Ministry of Public Health. Lebanese Soc Cardiol 2011. In-house data
- [12]Tohme RA, Jurjus AR, Estephan A: The prevalence of hypertension and its association with other cardiovascular disease risk factors in a representative sample of the Lebanese population. J Hum Hypertens 2005, 19:861-868.
- [13]World Health Organization: A global brief on Hypertension. Silent killer, global public health crisis. World Health Day 2013. Geneva, Switzerland: World Health Organization; 2013. Available from: http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf webcite. Last access: 8th of July 2013
- [14]Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004, 43:10-17.
- [15]Centers for Disease Control and Prevention (CDC): Vital signs: awareness and treatment of uncontrolled hypertension among adults — United States, 2003–2010. MMWR Morb Mortal Wkly Rep 2012, 61:703-709.
- [16]Knight EL, Bohn RL, Wang PS, Glynn RJ, Mogun H, Avorn J: Predictors of uncontrolled hypertension in ambulatory patients. Hypertension 2001, 38:809-814.
- [17]Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, ALLHAT Collaborative Research Group: Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002, 4:393-404.
- [18]Duggirala MK, Cuddihy RM, Cuddihy MT, Naessens JM, Cha SS, Mandrekar JN, Leibson CL: Predictors of blood pressure control in patients with diabetes and hypertension seen in primary care clinics. Am J Hypertens 2005, 18:833-838.
- [19]Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, et al.: 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
- [20]Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee: Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003, 42:1206-1252.
- [21]World Health Organization: BMI classification 2004. Geneva, Switzerland: World Health Organization; 2004. Available from: http://www.who.int/bmi/index.jsp?introPage=intro_3.html webcite
- [22]Viera AJ, Garrett JM: Understanding interobserver agreement: the Kappa Statistic. Fam Med 2005, 37:360-363.
- [23]Yoon PW, Gillespie CD, George MG, Wall HK: Control of hypertension among adults - national health and nutrition examination survey, United States, 2005–2008. MMWR Morb Mortal Wkly Rep 2012, 61:19-25.
- [24]Shelley D, Tseng TY, Andrews H, Ravenell J, Wu D, Ferrari P, Cohen A, Millery M, Kopal H: Predictors of blood pressure control among hypertensive in community health centers. Am J Hypertens 2011, 24:1318-1323.
- [25]Hicks LS, Shaykevich S, Bates DW, Ayanian JZ: Determinants of racial/ethnic differences in blood pressure management among hypertensive patients. BMC Cardiovasc Disord 2005, 5:16. BioMed Central Full Text
- [26]Majernick TG, Zacker C, Madden NA, Belletti DA, Arcona S: Correlates of hypertension control in a primary care setting. Am J Hypertens 2004, 17:915-920.
- [27]Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowitz DR: Hypertension control: how well are we doing? Arch Intern Med 2003, 163:2705-2711.
- [28]Wang JT, Vasan RS: Epidemiology of uncontrolled hypertension in the United States. Circulation 2005, 112:1651-1662.
- [29]Ferrannini E, Cushman WC: Diabetes and hypertension: the bad companions. Lancet 2012, 380:601-610.
- [30]Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR: Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. Hypertension 2011, 57:891-897.
- [31]Hirbli KI, Gerges TA, Karam VJ, Saikaly JA: The estimation of the prevalence of diabetes mellitus in Lebanon. J Med Liban 1992, 40:22-30. Article in French
- [32]Hirbli KI, Jambeine MA, Slim HB, Barakat WM, Habis RJ, Francis ZM: Prevalence of diabetes in Greater Beirut. Diabetes Care 2005, 28:1262.
- [33]O’Connor PJ, Vazquez-Benitez G, Schmittdiel JA, Parker ED, Trower NK, Desai JR, Margolis KL, Magid DJ: Benefits of early hypertension control on cardiovascular outcomes in patients with diabetes. Diabetes Care 2013, 36:322-327.
- [34]Nilsson PM, Gudbjörnsdottir S, Eliasson B, Cederholm J, Steering Committee of the National Diabetes Register, Sweden: Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden. J Hum Hypertens 2003, 17:37-44.
- [35]Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W, Papademetriou V, Weber M, ACCOMPLISH Investigators: Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007, 16:80-86.
- [36]Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS: Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012, 59:1124-1131.
- [37]Bobrie G: I-COMBINE Study Investigators. I-COMBINE Study: assessment of efficacy and safety profile of Irbesartan/Amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with Amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded–end point evaluation study. Clin Ther 2012, 34:1705-1719.
- [38]Prugger C, Keil U, Wellmann J, de Bacquer D, de Backer G, Ambrosio GB, Reiner Z, Gaita D, Wood D, Kotseva K, Heidrich J, EUROASPIRE III Study Group: Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. J Hypertens 2011, 29:1641-1648.
- [39]Ong KL, Cheung BM, Man YB, Lau CP, Lam KS: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007, 49:69-75.
- [40]Primatesta P, Brooks M, Poulter NR: Improved hypertension management and control: results from the Health Survey for England 1998. Hypertension 2001, 38:827-832.
- [41]Kenefick H, Lee J, Fleishman V: New England Healthcare Institute. Improving Physician Adherence to Clinical Practice Guidelines. Barriers and Strategies for Change. 2008.
- [42]Pickering TG, Gerin W, Schwartz AR: What is the white-coat effect and how should it be measured? Blood Press Monit 2002, 7:293-300.
- [43]Imai Y, Obara T, Asamaya K, Ohkubo T: The reason why home blood pressure measurements are preferred over clinic or ambulatory blood pressure in Japan. Hypertens Res 2013. In press
- [44]Agarwal R, Weir MR: Treated hypertension and the white coat phenomenon: office readings are inadequate measures of efficacy. J Am Soc Hypertens 2013, 7:236-243.
- [45]Shah S, Cook DG: Inequalities in the treatment and control of hypertension: age, social isolation and lifestyle are more important than economic circumstances. J Hypertens 2001, 19:1333-1340.
- [46]Lloyd-Jones DM, Evans JC, Levy D: Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005, 294:466-472.
- [47]Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, Miller CD, Ziemer DC, Barnes CS: Clinical Inertia. Ann Intern Med 2001, 135:825-834.
- [48]Feldman RD, Brass EP: From bad behavior to bad biology: pitfalls and promises in the management of resistant hypertension. Can J Cardiol 2013, 29:549-556.